Thu, Mar 5, 2015, 3:47 PM EST - U.S. Markets close in 13 mins.


% | $
Quotes you view appear here for quick access.


  • hollyscottman Feb 4, 2014 6:32 AM Flag

    Smart people will hang on to their shares and buy more for the following reasons

    The old CEO, Gary Rabin, is gone, which alone should have been grounds for a nice gain. ACT has added highly competent, experienced people to the board recently, and with the other positive news on the way, should have no issues finding a competent, experienced CEO to take the helm.

    Unfortunately, Gary's actions will cost ACT in the future, and not an insubstantial amount either. And like any normal biotech, ACT has faced enormous financial difficulties. Added to those usual difficulties is the fact that US law prohibits federal funding for stem cell research, which is extraordinarily expensive, so all of the funding for ACT's research has had to come from other sources. As is also the case with many companies just starting out, biotech or not, selling stock was part of the fund-raising effort. As it required a lot of funding, ACT issued a lot of shares, which has served to dilute the share value much as a printing currency devalues a country's currency.

    Having said that, and without making light of what are not minor concerns with the business side of ACT, and even given that ACT is a "penny stock" which are typically of no interest to me personally, I'm nevertheless convinced ACT is a solid investment for the long term, but which also has short-term potential. Here's why:

    Despite their past financial difficulties, those behind ACT have kept the company afloat, displaying tenacious dedication even when things got so bad the phones were switched off. If that sort of thing didn't kill them, now that the company has treatments in the works that already have years of testing behind them and has demonstrated their science is gold, one has solid reasons and evidence on which to base the belief that ACT will also overcome its current issues.

    Yahoo has a character limit, so I will add the rest of the information as a response to this post. Please check the comment section for the continuation.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Holly,
      Excellent post, remember the I cell board have many brilliant posters but over here you preaching the good word to those who can see but they do not believe that in matter of days Actc is about to change medicine forever, more lives will be touched positively with this tiny little gem of a company Actc than all the big pharmaceutical companies combined........................

      Sentiment: Hold

    • UP

      Sentiment: Strong Buy

    • Holly-

      The NEJM article is BS as it's not being published according to "investor relations" for ACTC. I spoke with a friend who spoke to them and the Italy thing was not correct. In fact, "investor relations" did not confirm a paper was even being written for publication in any journal.

      • 2 Replies to krycap64
      • hollyscottman Feb 5, 2014 6:16 PM Flag

        Well, let's look at the evidence then. First, we have an audio recording of Dr. Hubschman in Rome, to which I've personally listened, who said that the results were going to be published in the NEJM. In addition, there is this from an article in the Telegraph:

        "News on general results from the trial, the first of three phases of human testing typically required by the Food and Drug Administration, is 'imminent' and will be followed by an in-depth presentation at a conference or in a medical journal, Advanced Cell spokesman David Schull said."


        Claim from random person on Internet saying they heard from another person who heard from yet another person, ostensibly someone from ACT, that there will be no paper.

        Given those conflicting bits of info, I'm going to go with the first option as there is actual evidence to support it.

        Neither Huschman nor Schull gave an exact date. I mentioned as much regarding Hubschman's remarks not only in this thread, but in others as well. I get that people are excited, but nobody said it would be this week, or even this month or next. Many hoped it would be today, but hope and speculation are merely that.

        Personally, I'm absolutely fine with the info not being published today. That leaves more time for others to hear about it, and contrary to what one might assume, I'm not going to be disappointed if the pps drops; it would provide an opportunity to pick up shares at a lower cost.

      • krycap, "investor relations" knows nothing until after it has been officially announced, and sometimes not even then.

        Sentiment: Strong Buy

    • I'll wait for the uplisting and drop, then it's time to buy.

    • Re: Smart people will hang on to their shares and buy more for the following reasons ....

      Ignore Investment Tips from Stock Message Boards, Say Researchers

      Prabhudev Konana, Alok Kumar, Raj Raghunathan and Bin Gu are Ph.D. researchers in marketing, finance and information systems at The University of Texas at Austin and the University of Miami. They claim message boards cause good investors to make bad decisions. "It's not as simple as saying, 'Well, it is harmless entertainment,'" says researcher Kumar. "There is real risk you will be influenced by the 'noise' and begin to amplify your own investment biases."

      "Individual investors exhibit what is called confirmation bias," says Konana. "They select and read information that conforms to their own preconceived biases, and as a result they actually become more confident in their opinion and trade more frequently, but with lower overall returns." This runs counter to the concept that investors are rational information gatherers. "Behavioral finance studies tell us investors are subject to all manner of psychological biases," he says. "And message boards contribute to these biases, actually amplifying them, particularly for investors with strongly held opinions."

      : )

      • 2 Replies to beareclawe
      • hollyscottman Feb 5, 2014 7:01 AM Flag

        I completely agree with that, which is why I said in another comment on this thread: "Don't simply take my word on it, however. Conduct your due diligence and make a decision based on the evidence." Based on evidence = not relying on "gut" feelings and emotions.

        That is not only fundamental to successful investing, but to every subject. Whether it's buying a car or religion, if people first investigated rather than simply accepting what they're told, if they insisted on evidence before developing a belief, they could avoid believing a whole lot of nonsensical #$%$.

    • hollyscottman Feb 4, 2014 6:34 AM Flag

      The three human studies currently underway are listed on with expected completion dates of January 2014. To clarify: one trial gave an expected completion date of July 2013 for the study, with the date of late January 2014 for completing the review of the data. The other two studies give dates of January 2014 for completion of the initial study. At a medical conference in Rome less than two weeks ago, the doctor presenting information on the treatments, Dr. Hubschman who participated in conducting studies, said all patients have reported an improvement in visual acuity and zero safety issues arose.

      (Note: these studies are intended to determine the safety of the treatment, not improvement in visual acuity. That we know the patients reported improvement in their visual acuity is a bonus; indicative the phase meant to test for efficacy of the treatment will provide positive results, as well.)

      A paper is due to be published in the New England Journal of Medicine, possibly detailing the trial info. Dr. Hubschman did not mention a specific date for publication. It could be as early as tomorrow, as the NEJM is released online on Wednesday, or it could be we will need to wait a bit longer.

      Publishing positive trial results, and we have every reason to expect it will be the case that the results will prove positive, opens the door to a possible joint venture, which would help to fund the company and drive the stock sharply upward, and the possibility of being granted "Breakthrough Status" with the FDA, which would fast-track remaining clinical trials and, ostensibly, get the treatments to market faster.

      Yahoo has a character limit, so I will add the rest of the information as a response to this post. Please check the response link for the continuation.

      • 2 Replies to hollyscottman
      • Re: ......., opens the door to a possible joint venture, which would help to fund the company and drive the stock sharply upward, and the possibility of being granted "Breakthrough Status" with the FDA, which would fast-track remaining clinical trials and, ostensibly, get the treatments to market faster.


        : )

      • hollyscottman Feb 4, 2014 6:36 AM Flag

        The above point is of great interest to those who want to hang on until their shares have multiplied many times over in value -- there will be no advanced notice. One day you will wake up to find ACTC is skyrocketing in the wake of an announcement and you will have missed out.

        There are veterinary medicine trials underway at Tuft's University for treatments dealing with five relatively common ailments, and vet meds get to market in far less time than human meds. If successful, profits from the vet med profits could carry the company while they wait on the additional human clinical trial phases to be conducted.

        While Dr. Lanza is the public face of ACT, some of the brightest minds in stem cells are also part of the ACT team. Irina Klimanskaya for example, a brilliant, tenacious researcher who came to the team from Harvard University and is highly accomplished in her own right. Or Dr. Robert Langer, who is an Institute Professor at the Massachusetts Institute of Technology and recently appeared in a televised award ceremony in which he was given a "Breakthrough Prize in Life Sciences" and who is also on the ACT Board of Directors.

        ACT gains its stem cells via the same process used for genetic testing of embryos, meaning they use the same method employed to test embryos in which a single cell is extracted, for parents who might have a genetic condition and want to check if it has been passed to their child, and so does not require destruction of the embryo, which in turn means ACT is not subject to many of the ethical objections raised against other companies.

        Please see the response to this post for the continuation.

6.97+0.17(+2.50%)Nov 13 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.